๐จ๐ฆ ์บ๋๋ค ยท "DOUBLED" ยท ์ด 2๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 696๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 1๊ฑด(0.1%)ยท์ค๋ฆฝ 695๊ฑด(99.9%)ยท๋ถ์ 0๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 0.0(์ค๋ ๊ท ํ)์ ๋๋ค.
Medical oncologist Dr. Jennifer Knox independently reviewed a U.S.-led study of the experimental drug daraxonrasib and calls the results "amazing."
TORONTO โ The head of pancreatic cancer at Princess Margaret Cancer Centre says she hopes clinical trials for a pill that could double survival time will soon be open to Canadian patients. Medical oncologist Dr. Jennifer Knox independently reviewed a U.S.-led study of the experimental drug daraxonrasib and calls the results โamazing.โ The randomized Phase [โฆ]